Clinical Trial Update: Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating irradiated PD-L1 CAR-NK cells in combination with pembrolizumab and N-803 for recurrent/metastat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Junction Cancer
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Irradiated PD-L1 CAR-NK cells
• N-803
• Pembrolizumab (Keytruda) (pembrolizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC | Phase 2 | Status: ACTIVE_NOT_RECRUITING